

Australia's Life Sciences Ecosystem – Opportunities in Medtech

Nichi-Go Global x J-Bridge Webinar

Thursday, 26 May 2022, 4:00-5:15pm AEST / 3:00-4:15pm JST

BACKGROUND

The Nichi-Go Global x J-Bridge webinar series, an initiative of five Australian state governments, JETRO and the Consulate-General of Japan in Sydney, supported by the AJBCC, Innovation Dojo and the Consulate-General of Japan in Melbourne, is designed to highlight the potential of innovative Australian companies to forward-thinking Japanese corporations. The sole aim is to add value through Japan-Australia synergy, and the Australian companies we select are pre-screened for viability. Five events were planned for 2022, focusing on the sectors of Cyber Security (24 February), Med-Tech (26 May), Ag-Tech (30 June), Clean Energy (1 September) and Space / AI / Robotics (24 November).

The series is a collaborative effort with JETRO's J-Bridge program, which promotes business collaboration and alliances between Japanese companies and overseas start-ups and companies.

The second event in the series will be delivered by Global Victoria and will highlight the breadth of opportunities in medtech, showcasing one high-potential company from each participating state.

HOW TO ATTEND

WHEN:

Thursday, 26 May 2022

TIME:

4:00pm to 5:15pm AEST / 3:00pm to 4:15pm JST

WHERE:

Zoom webinar

LANGUAGE:

The event will be held in English and Japanese.


IMPORTANT INFORMATION

- ▶ You must register your intent to attend the webinar at jetro.go.jp/form5/pub/syd/220526
- ▶ After you register, you will receive a confirmation email with a Zoom link.
- ▶ Please add the details to your calendar.
- ▶ Learn more about JETRO's J-Bridge Program at jetro.go.jp/en/j-bridge



Australia's Life Sciences Ecosystem – Opportunities in Medtech

Nichi-Go Global x J-Bridge Webinar



PARTICIPATING COMPANIES AND SPEAKERS

VICTORIA RHINOMED



Michael Johnson
CEO and Managing Director

Rhinomed is a global MedTech company enhancing respiration, sleep, diagnosis of upper respiratory disease and nasal drug delivery. Rhinomed's existing CE, FDA and TGA registered nasal products have been worn comfortably and safely since 2016, with 1.2 million users registering over 30 million positive user experiences. Rhinomed has developed comfortable, clinically proven nasal swabs called Rhinoswab and Rhinoswab Junior that deliver superior sample collection for self-collection by adults and children.

R H I N O M E D

QUEENSLAND LEVO ORTHOTICS



Masanori Shimamura
DOLA Japan Instructor, Translator

A new concept in healthcare providing worldwide access to our team of Australian Podiatrists & Orthotic laboratory. Complete our online consultation questions and record a little video to show us how you stand and walk. Our expert eyes will assess how you stand and walk, just like you were visiting one of our clinics in Australia. Your Podiatrist will design and send your Prescription Orthotics to correct your foot problems, help your musculoskeletal health and prevent future problems



NEW SOUTH WALES PROSPECTION



Kaoru Sato
Director of Customer Success/
Country Manager – Japan

Prospection is a pioneer in health data analytics technology. Combining advanced AI/ML algorithms and real world data to unearth health journey insights. Providing actionable real-world evidence that enables better outcomes for patients, across Japan, Asia-Pacific, UK, and USA. We analyse large health care data sets (script claims, EMR, Registry, Insurance, Commercial Supply Chain), to better understand the healthcare journey.



SOUTH AUSTRALIA FUSETEC 3D



Mark Roe

Fusetec is an IP centric company, founded to answer the research question, "How Do Surgeons Train." Our mission is to improve healthcare outcomes by providing safe, affordable, and effective training alternatives to upskill residents and continually advance surgeon training. The use of cadavers in surgical training is costly, potentially infectious, highly regulated, with limited access to pathology. Fusetec manufactures anatomically accurate, fully operable, surgical models for simulation training and recently opened our first 25 bed 'Advanced Surgical Training Clinic' in Adelaide.



WESTERN AUSTRALIA ARGENICA THERAPEUTICS



Dr Liz Dallimore
Chief Executive Officer

Argenica Therapeutics (ASX:AGN) is an Australian biotechnology company developing novel therapeutics to reduce brain tissue death after stroke and other brain injuries. Our lead drug candidate, ARG-007, has been successfully demonstrated to improve outcomes in pre-clinical animal models of brain injury, and will shortly commence Phase 1 clinical trials in humans. The aim is for our therapeutic to be administered by first responders to protect brain tissue against damage during a stroke and other types of brain injury.



**Thursday,
26 May 2022**

**4:00-5:15pm AEST /
3:00-4:15pm JST**

